A framework for identification of on- and off-target transcriptional responses to drug treatment

Owing to safety concerns or insufficient efficacy, few drug candidates are approved for marketing. Drugs already on the market may be withdrawn due to adverse effects (AEs) discovered after market introduction. Comprehensively investigating the on-/off-target effects of drugs can help expose AEs during the drug development process. We have developed an integrative framework for systematic identification of on-/off-target pathways and elucidation of the underlying regulatory mechanisms, by combining promoter expression profiling after drug treatment with gene perturbation of the primary drug target. Expression profiles from statin-treated cells and HMG-CoA reductase knockdowns were analyzed using the framework, allowing for identification of not only reported adverse effects but also novel candidates of off-target effects from statin treatment, including key regulatory elements of on- and off-targets. Our findings may provide new insights for finding new usages or potential side effects of drug treatment.

[1]  William DuMouchel,et al.  Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System , 1999 .

[2]  C. Stancu,et al.  Statins: mechanism of action and effects , 2001, Journal of cellular and molecular medicine.

[3]  B. Rovin,et al.  A novel interleukin-8 polymorphism is associated with severe systemic lupus erythematosus nephritis. , 2002, Kidney international.

[4]  G. Thorgeirsson,et al.  Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S) , 2004, The Lancet.

[5]  U. Pati,et al.  Over‐expression of TATA binding protein (TBP) and p53 and autoantibodies to these antigens are features of systemic sclerosis, systemic lupus erythematosus and overlap syndromes , 2004, Clinical and experimental immunology.

[6]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[7]  G. Baumann,et al.  Effect of statins on the proteasomal activity in mammalian endothelial and vascular smooth muscle cells. , 2005, Biochemical pharmacology.

[8]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[9]  J. Owczarek,et al.  Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. , 2007, Pharmacological reports : PR.

[10]  P. Macfarlane,et al.  Long-term follow-up of the West of Scotland Coronary Prevention Study. , 2007, The New England journal of medicine.

[11]  C. Robert,et al.  Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. , 2008, Archives of dermatology.

[12]  Jesse A Berlin,et al.  Adverse event detection in drug development: recommendations and obligations beyond phase 3. , 2008, American journal of public health.

[13]  C. Heng,et al.  Effects of atherogenic diet and atorvastatin treatment on gene expression profiles in the C57BL/6J mouse liver. , 2008, Gene expression.

[14]  Yan Leng,et al.  Multiple roles of HDAC inhibition in neurodegenerative conditions , 2009, Trends in Neurosciences.

[15]  L. Groop,et al.  Epigenetics: A Molecular Link Between Environmental Factors and Type 2 Diabetes , 2009, Diabetes.

[16]  Martin S. Taylor,et al.  The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line , 2009, Nature Genetics.

[17]  Sabrina Koperski,et al.  This material is the copyright of the original publisher. Unauthorised copying and distribution is prohibited. Amyotrophic Lateral Sclerosis-Like Conditions in Possible Association with Cholesterol-Lowering Drugs , 2009 .

[18]  Hong Wang,et al.  The FOX transcription factors regulate vascular pathology, diabetes and Tregs. , 2009, Frontiers in bioscience.

[19]  Yasuo Ohashi,et al.  Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2010, The Lancet.

[20]  Aaron R. Quinlan,et al.  BIOINFORMATICS APPLICATIONS NOTE , 2022 .

[21]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[22]  Han-Chang Huang,et al.  Targeting HDACs: A Promising Therapy for Alzheimer's Disease , 2011, Oxidative medicine and cellular longevity.

[23]  Xiaohong Chen,et al.  Statins: Multiple neuroprotective mechanisms in neurodegenerative diseases , 2011, Experimental Neurology.

[24]  M. Vizcaychipi,et al.  Statins: the role in the treatment and prevention of Alzheimer's neurodegeneration. , 2011, Journal of Alzheimer's disease : JAD.

[25]  Jianghua Chen,et al.  Dual effects of statins therapy in systemic lupus erythematosus and SLE-related atherosclerosis: the potential role for regulatory T cells. , 2012, Atherosclerosis.

[26]  P Ryan,et al.  Novel Data‐Mining Methodologies for Adverse Drug Event Discovery and Analysis , 2012, Clinical pharmacology and therapeutics.

[27]  Gang Xiao,et al.  Signification of Hypermethylated in Cancer 1 (HIC1) as Tumor Suppressor Gene in Tumor Progression , 2012, Cancer Microenvironment.

[28]  John J. McNeil,et al.  The Value of Patient-Centred Registries in Phase IV Drug Surveillance , 2010, Pharmaceutical Medicine.

[29]  Carsten O. Daub,et al.  MOIRAI: a compact workflow system for CAGE analysis , 2014, BMC Bioinformatics.

[30]  D. Ye,et al.  E2F1: a potential therapeutic target for systematic lupus erythematosus , 2014, Rheumatology International.

[31]  T. Steele,et al.  Statins inhibit proliferation and cytotoxicity of a human leukemic natural killer cell line , 2013, Biomarker Research.

[32]  Charity W. Law,et al.  voom: precision weights unlock linear model analysis tools for RNA-seq read counts , 2014, Genome Biology.

[33]  R. Heltsley,et al.  Urine drug testing of chronic pain patients. V. Prevalence of propoxyphene following its withdrawal from the United States market. , 2013, Journal of analytical toxicology.

[34]  H. Grover,et al.  Are statins really wonder drugs? , 2014, Journal of the Formosan Medical Association = Taiwan yi zhi.

[35]  Cesare Furlanello,et al.  A promoter-level mammalian expression atlas , 2015 .

[36]  Prasad Kulkarni,et al.  How Drugs are Developed and Approved by the FDA: Current Process and Future Directions , 2014, The American Journal of Gastroenterology.

[37]  V. Trajković,et al.  Statin-mediated inhibition of cholesterol synthesis induces cytoprotective autophagy in human leukemic cells. , 2015, European journal of pharmacology.

[38]  Pau-Chung Chen,et al.  Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A nationwide population-based cohort study. , 2015, Atherosclerosis.

[39]  T. Hamazaki,et al.  Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms , 2015, Expert review of clinical pharmacology.

[40]  D. Slakey,et al.  The impact of statins on biological characteristics of stem cells provides a novel explanation for their pleiotropic beneficial and adverse clinical effects. , 2015, American journal of physiology. Cell physiology.

[41]  M. Obeidat,et al.  Impact of Statins on Gene Expression in Human Lung Tissues , 2015, PloS one.

[42]  Alessandro Didonna,et al.  The promise and perils of HDAC inhibitors in neurodegeneration , 2014, Annals of clinical and translational neurology.

[43]  Michael J. Keiser,et al.  Systems pharmacology augments drug safety surveillance , 2014, Clinical pharmacology and therapeutics.

[44]  Samik Ghosh,et al.  Elucidation of the molecular mechanisms underlying adverse reactions associated with a kinase inhibitor using systems toxicology , 2015, npj Systems Biology and Applications.

[45]  Jinkai Xu,et al.  Simvastatin induces growth inhibition and apoptosis in HepG2 and Huh7 hepatocellular carcinoma cells via upregulation of Notch1 expression. , 2015, Molecular medicine reports.

[46]  R. W. Hansen,et al.  Journal of Health Economics , 2016 .

[47]  Christos G Mihos,et al.  Effects of Statin Therapy in Patients with Systemic Lupus Erythematosus , 2016, Southern medical journal.

[48]  S. Grundy.  Primary prevention of cardiovascular disease with statins: Assessing the evidence base behind clinical guidance , 2016 .

[49]  S. Kimbung,et al.  High expression of cholesterol biosynthesis genes is associated with resistance to statin treatment and inferior survival in breast cancer , 2016, Oncotarget.

[50]  Junqiang Yan,et al.  Neuroprotective mechanisms of statins in neurodegenerative diseases , 2016 .

[51]  S. Ostad,et al.  Investigation of simvastatin-induced apoptosis and cell cycle arrest in cancer stem cells of MCF-7. , 2016, Journal of cancer research and therapeutics.

[52]  Amber Jessup,et al.  Key cost drivers of pharmaceutical clinical trials in the United States , 2016, Clinical trials.

[53]  Chiehfeng Chen,et al.  Lovastatin lowers the risk of breast cancer: a population-based study using logistic regression with a random effects model , 2016, SpringerPlus.

[54]  Y. Terauchi,et al.  Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model. , 2016, European journal of pharmacology.

[55]  Douglas K Owens,et al.  Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. , 2016, JAMA.

[56]  Jie Luo,et al.  Discovery of a potent HMG-CoA reductase degrader that eliminates statin-induced reductase accumulation and lowers cholesterol , 2018, Nature Communications.